Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

Meletios Dimopoulos, Sosana Delimpasi, Salomon Manier, Jean-Marie Michot, Enrique Ocio, Samuel Rubinstein, Joselle Cook, Maria Del Carmen Martinez Chamorro, Aurora Breazna, Amishi Dhadwal, Yogita Ghodke, Sheila Masinde, Glenn Kroog, Shawn Sarkaria, Albert Oriol

Blood (2025) 146 (Supplement 1): 2254.

https://doi.org/10.1182/blood-2025-2254

Published: 2025

Journal Articles

Development of clinical manifestations in antiphospholipid antibodies carriers according to the 2023 acr/EULAR serological domains

Blood (2025) 146 (Supplement 1): 851.

https://doi.org/10.1182/blood-2025-851

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Blood (2025) 146 (Supplement 1): 701.

https://doi.org/10.1182/blood-2025-701

Published: 2025

Journal Articles

Effectiveness and toxicity of cyclophosphamide, etoposide, and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non-Hodgkin lymphoma

Marina Herrero López, Sara Fernandez-Luis, Miriam Sánchez Escamilla, Irene Gorostidi Álvarez, Julia Bannatyne Undabeitia, María Oviedo Madrid, José Flores García, Ana Gea Peña, Sonia González De Villambrosia, Javier Nuñez, Lucrecia Yanez San Segundo, Enrique Ocio, María Bermúdez Rodríguez

Blood (2025) 146 (Supplement 1): 3686.

https://doi.org/10.1182/blood-2025-3686

Published: 2025

Journal Articles

Factors associated with the development of second primary malignancies after allogeneic stem cell hematopoietic transplantation. no association with In Vivo T-cell depletion

Juan Manuel Cerezo-Martin, Guillermo Martin, Lucrecia Yanez San Segundo, Ana Tobalina, Ana Gea, Julia Bannatyne Undabeitia, María Oviedo Madrid, Irene Gorostidi Álvarez, José Flores García, Marina Herrero López, Elba Velez, Irene Fernández, Mercedes Colorado, Miriam Sánchez Escamilla, Jose Iñigo Romón, Monica Lopez-Duarte, Enrique Ocio, Arancha Bermúdez

Blood (2025) 146 (Supplement 1): 6048.

https://doi.org/10.1182/blood-2025-6048

Published: 2025

Journal Articles

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Gurdeep Parmar, Miles Prince, Enrique Ocio, Chatchada Karanes, Sumit Madan, Albert Oriol, Pierre Bories, Michel Delforge, Nashat Gabrail, Dorothee Semiond, Nan Jia, Sandrine Macé, Florence Suzan, Helgi van de Velde, Hang Quach

Blood (2021) 138 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2021-147136

Published: 2021

Journal Articles

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Blood (2021) 138 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2021-147812

Published: 2021

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Blood (2021) 138 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2021-146188

Published: 2021

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2021-148423

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

Development of clinical manifestations in antiphospholipid antibodies carriers according to the 2023 acr/EULAR serological domains

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Effectiveness and toxicity of cyclophosphamide, etoposide, and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non-Hodgkin lymphoma

Factors associated with the development of second primary malignancies after allogeneic stem cell hematopoietic transplantation. no association with In Vivo T-cell depletion

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only